Centiva Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.8M | Sell |
48,515
-33,218
| -41% | -$1.91M | 0.02% | 372 |
|
|
2026
Q1 | $4.96M | Sell |
81,733
-40,450
| -33% | -$2.36M | 0.04% | 280 |
|
|
2025
Q4 | $6.59M | Buy |
+122,183
| New | +$5.88M | 0.05% | 217 |
|
|
2025
Q3 | – | Sell |
-10,859
| Closed | -$503K | – | 1153 |
|
|
2025
Q2 | $503K | Buy |
+10,859
| New | +$533K | 0.01% | 951 |
|
|
2025
Q1 | – | Sell |
-19,671
| Closed | -$1.11M | – | 1581 |
|
|
2024
Q4 | $1.11M | Buy |
19,671
+1,580
| +9% | +$88.3K | 0.02% | 503 |
|
|
2024
Q3 | $936K | Buy |
+18,091
| New | +$849K | 0.02% | 891 |
|
|
2024
Q1 | – | Sell |
-31,945
| Closed | -$1.63M | – | 1791 |
|
|
2023
Q4 | $1.64M | Buy |
31,945
+13,530
| +73% | +$710K | 0.04% | 419 |
|
|
2023
Q3 | $1.07M | Sell |
18,415
-9,023
| -33% | -$553K | 0.02% | 600 |
|
|
2023
Q2 | $1.75M | Buy |
27,438
+20,040
| +271% | +$1.34M | 0.04% | 420 |
|
|
2023
Q1 | $513K | Sell |
7,398
-17,043
| -70% | -$1.2M | 0.01% | 826 |
|
|
2022
Q4 | $1.76M | Buy |
24,441
+16,076
| +192% | +$1.21M | 0.05% | 395 |
|
|
2022
Q3 | $594K | Sell |
8,365
-7,669
| -48% | -$556K | 0.01% | 822 |
|
|
2022
Q2 | $1.24M | Sell |
16,034
-4,076
| -20% | -$310K | 0.03% | 517 |
|
|
2022
Q1 | $1.47M | Buy |
+20,110
| New | +$1.35M | 0.03% | 551 |
|
|
2021
Q4 | – | Sell |
-18,696
| Closed | -$1.1M | – | 1215 |
|
|
2021
Q3 | $1.11M | Buy |
18,696
+13,571
| +265% | +$894K | 0.07% | 308 |
|
|
2021
Q2 | $342K | Sell |
5,125
-2,160
| -30% | -$141K | 0.01% | 996 |
|
|
2021
Q1 | $460K | Sell |
7,285
-9,080
| -55% | -$565K | 0.02% | 604 |
|
|
2020
Q4 | $1.01M | Buy |
+16,365
| New | +$1.01M | 0.04% | 269 |
|
|
2020
Q3 | – | Sell |
-32,013
| Closed | -$1.88M | – | 698 |
|
|
2020
Q2 | $1.88M | Sell |
32,013
-4,492
| -12% | -$269K | 0.11% | 109 |
|
|
2020
Q1 | $2.04M | Buy |
36,505
+2,006
| +6% | +$123K | 0.09% | 139 |
|
|
2019
Q4 | $2.21M | Buy |
34,499
+30,278
| +717% | +$1.73M | 0.11% | 185 |
|
|
2019
Q3 | $214K | Sell |
4,221
-19,941
| -83% | -$937K | 0.01% | 496 |
|
|
2019
Q2 | $1.1M | Sell |
24,162
-26,078
| -52% | -$1.21M | 0.07% | 200 |
|
|
2019
Q1 | $2.4M | Buy |
50,240
+28,490
| +131% | +$1.42M | 0.16% | 101 |
|
|
2018
Q4 | $1.13M | Buy |
21,750
+20,522
| +1,671% | +$1.1M | 0.09% | 130 |
|
|
2018
Q3 | $76K | Buy |
+1,228
| New | +$72.9K | 0.01% | 174 |
|
Other funds holding BMY
Centiva Capital's BMY Position: Q2 2026 in Review
Centiva Capital reduced its Bristol-Myers Squibb (BMY) stake by 41% in Q2 2026, selling an estimated $1.91M and leaving 48,515 shares worth $2.8M. The position accounts for 0.02% of the portfolio, ranked #372.
Centiva Capital first reported a position in BMY in Q3 2018 and has held it in 26 quarters since. The position peaked at $6.59M in Q4 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Centiva Capital held 48,515 shares of Bristol-Myers Squibb worth $2.8M as of Q2 2026.
- Centiva Capital sold 33,218 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.91M.
- Bristol-Myers Squibb made up 0.02% of Centiva Capital's portfolio in Q2 2026, its #372 holding.
- Centiva Capital first reported a position in Bristol-Myers Squibb in Q3 2018 and has held it in 26 quarters since.
- Centiva Capital's Bristol-Myers Squibb position peaked at $6.59M in Q4 2025.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.